Marcio Souza, Praxis Precision Medicines CEO
Praxis' epilepsy drug reduces seizures by 46% in pediatric patients in Phase 2 study
Praxis Precision Medicines released another batch of topline data from its epilepsy program on Tuesday, this time from the Phase 2 EMBOLD study investigating relutrigine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.